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all power of the model, whilst a significant improvement was obtained after entering
redox pattern data (Figure).
Conclusions: The assessment of redox pattern yields incremental diagnostic value over
clinical and biochemical data in predicting CAV. In particular, GSHe may represent a clin-
ically useful marker of risk.
11:30 a.m.
813-3 Reduction of Plasma Cholesterol and Fibrinogen by 
H.E.L.P. Apheresis Increases Myocardial Perfusion in 
Heart Transplant Patients
Beate R. Jaeger, Frank Bengel, Kenichi Odaka, Carlos A. Labarrere, Stefan Bengsch, 
Clemens Engelschalk, Eckart Kreuzer, Peter Ueberfuhr, Bruno Reichart, Dietrich Seidel, 
Klinikum der Universitat Muenchen, Technische Universitaet Muenchen, Muenchen, 
Germany, Methodist Research Institute, Clarian Health Partners, Indianapolis, IN
Introduction and Hypothesis: Given the central importance of the microvasculature in
heart transplant patients, we investigated the possibility of increasing cardiac perfusion
following reduction of LDL-cholesterol and fibrinogen plasma levels after apheresis treat-
ment in transplanted hearts.
Methods: Ten long-term heart transplant recipients were examined with positron emis-
sion tomography (PET) to measure myocardial perfusion before and after a single Hep-
arin-mediated Extracorporeal LDL Precipitation (H.E.L.P.) apheresis treatment. H.E.L.P.
apheresis reduced the plasma levels of LDL-cholesterol and lipoprotein (a) by 48%
(p<.001), fibrinogen by 42% (p<.002), plasma viscosity by 14%, and erythrocyte aggre-
gation by 28%. Osmolality (<1%) and hematocrit (<1%) remained unchanged. The PET
studies were performed the mornings before and after the apheresis treatment. Myocar-
dial blood flow at rest and during adenosine-induced hyperemia was measured using
13N-ammonia.
Results: A single apheresis treatment significantly increased myocardial blood flow at
rest by 17.5% (p<.01) and hyperemic flow by 27% (p=.02). Coronary flow reserve
increased by 9% (p=.09). Hyperemic flow following adenosine infusion increased plasma
VEGF levels only before H.E.L.P. apheresis, indicating a better ischemic tolerance after
apheresis.
Conclusion: Myocardial perfusion in transplanted hearts significantly increases following
H.E.L.P. apheresis treatment. The present study provides complementary evidence to
clinical long-term studies demonstrating that cholesterol reduction either with statins and/
or apheresis improves heart transplant outcome.
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813-4 Smooth Muscle Cell Proliferation Index Correlates With 
Indium-111 Z2D3 Antibody Uptake in a Transplant 
Vasculopathy Swine Model
Javier Jimenez, Dillip Sawatt, Tammy Donahay, Lorraine Schofield, Ban An Khaw, Lynne 
L. Johnson, Rhode Island Hospital, Providence, RI
Background: Smooth muscle cell (SMC) proliferation is a hallmark of transplant vascul-
opathy (TV). The goal of this study was to determine the ability of gamma camera imag-
ing of a monoclonal antibody (Z2D3) tagged with Indium-111 to detect TV.
Methods: Coronary to right carotid transplantation was performed in 10 Yucatan mini
pigs using farm pigs as donors. In 5 of these experiments the RC was also grafted into
the LC (homografts) and in one farm pig the LC and RC were switched. After 44±22 days
animals were injected with BrdU, underwent planar and SPECT imaging and were sacri-
ficed and vessels removed. Tissue was sectioned and stained. Quantitative morphome-
try was performed. SMC proliferation index (BrdU-actin cells/actin x 100), was correlated
with in vivo and ex vivo uptake.
Results: Patency was obtained in only 5/10 allografts and 3/7 homografts. Six of the
scans were positive for focal tracer uptake in the neck and 10 were negative. Actin +/
BrdU + cells were seen in the media of allografts and in the recanalized lumen of
occluded homografts. A SMC proliferative index of 30% was used as a cut-off for scan
poistivity. By chi square there was significant concordance in 14 experiments and discor-
dance in 2 (p=0.008). When ex-vivo vessel counts were correlated with SMC proliferation
index there was a significant correlation with r2=0.528 (p<0.01).
Conclusion: The use of the monoclonal antibody Z2D3 tagged with Indium-111 allows
the detection of proliferating SMC and correlates with the intensity of cell proliferation.
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813-5 Should Statin Therapy Be Used Routinely in Pediatric 
Heart Transplant Recipients?
William T. Mahle, Robert N. Vincent, Alexandria N. Berg, Kirk R. Kanter, Emory 
University School of Medicine, Atlanta, GA
Background: The routine use of statin therapy has been shown to reduce significantly the
risk of developing coronary allograft vasculopathy (CAV) in adult heart transplant recipi-
ents. As such, we instituted a practice of routine pravastatin therapy for all pediatric trans-
plant patients regardless of lipid status starting in 1998. Whether statin therapy lowers
the risk of developing CAV following heart transplantation in children, however, is not
known. Methods: All pediatric patients who had undergone cardiac transplantation at our
institution from 1988-2002 were retrospectively reviewed. Pravastatin was administered
at doses of 0.2-0.3mg/kg/day. There were 331 person-years of pravastatin treatment.
CAV was diagnosed either by coronary angiography or at autopsy. Freedom of CAV was
analyzed by Cox-proportional hazards. Results: A total of 129 infants and children under-
went 142 heart transplants at a median age of 7.3 yrs. CAV developed in 25 subjects
(17.6%). Freedom from CAV was 80% at 5 years. In multivariable analysis use of pravas-
tatin therapy was associated with a significant reduction in CAV (p=0.03). Factors associ-
ated with an increased risk of CAV were increased frequency of late rejection and earlier
year of transplant (table). Conclusions: Pravastatin usage is associated with a lower inci-
dence of CAV in pediatric heart transplant recipients. Statin therapy should be consid-
ered in the routine maintenance regimen following heart transplantation in children.
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814-1 Transendocardial Injection of Autologous Bone Marrow 
Mononuclear Cells May Enhance Myocardial Viability 
Around Cell Injection Site
Emerson C. Perin, Hans F. Dohmann, Radovan Borejevic, Joao A. Assad, Guilherme V. 
Silva, Suzana A. Silva, Andre L. Sousa, William K. Vaughn, Isabel Rossi, Antonio C. 
Carvalho, Yong J. Geng, Hans J. Dohmann, James T. Willerson, Texas Heart Institute, 
Houston, TX, Pro-Cardiaco Hospital, Rio de Janeiro, Brazil
Background: Autologous Bone Marrow Mononuclear Cell (ABMMC) injection in humans
has shown improvement in areas reversible perfusion defects possibly through the pro-
motion of localized angiogenesis. Electromechanical voltage maps (EMVM) are capable
of assessing myocardial viability through the magnitude of underlying myocardial electri-
cal signals. Improvement in voltage values of previously non-viable tissue surrounding
cell injection sites was observed. We sought to systematically determine if ABMMC injec-
tions might expand areas of myocardial viability.
Methods: Fourteen pts (60 ± 10 y, 12 males) with ischemic cardiomyopathy were treated
with ABMMC transendocardial injections in a target area of reversible defect by SPECT
and viability by EMVM voltage criteria. Average electrical unipolar voltage was quantified
in the injected area and in the area surrounding injections (peri-injection area) immedi-
ately before and 4 months after the procedure. To assess the reproducibility of EMVM a
Risk Factors for CAV
Hazard Ratio CI P
Statin Therapy 0.29 0.09 – 0.96 0.03
Late Rejection 2.27 1.31 – 3.92 0.003
Earlier Year of Transplant 2.03 1.03 – 4.16 0.04
